248 related articles for article (PubMed ID: 28724846)
1. Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
Al-Tahami BAM; Al-Safi Ismail AA; Sanip Z; Yusoff Z; Shihabudin TMT; Singh TSP; Rasool AHG
J Nippon Med Sch; 2017; 84(3):125-132. PubMed ID: 28724846
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
[TBL] [Abstract][Full Text] [Related]
5. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
[TBL] [Abstract][Full Text] [Related]
6. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
[TBL] [Abstract][Full Text] [Related]
7. Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity.
Borges RL; Ribeiro-Filho FF; Carvalho KM; Zanella MT
Arq Bras Cardiol; 2007 Dec; 89(6):409-14. PubMed ID: 18317625
[TBL] [Abstract][Full Text] [Related]
8. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
11. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
Bougoulia M; Triantos A; Koliakos G
Hormones (Athens); 2006; 5(4):259-69. PubMed ID: 17178701
[TBL] [Abstract][Full Text] [Related]
12. Obesity indices and metabolic markers are related to hs-CRP and adiponectin levels in overweight and obese females.
Sanip Z; Ariffin FD; Al-Tahami BA; Sulaiman WA; Rasool AH
Obes Res Clin Pract; 2013; 7(4):e315-20. PubMed ID: 24306161
[TBL] [Abstract][Full Text] [Related]
13. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
Valsamakis G; McTernan PG; Chetty R; Al Daghri N; Field A; Hanif W; Barnett AH; Kumar S
Metabolism; 2004 Apr; 53(4):430-4. PubMed ID: 15045687
[TBL] [Abstract][Full Text] [Related]
14. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
[TBL] [Abstract][Full Text] [Related]
15. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
[TBL] [Abstract][Full Text] [Related]
16. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
Aydin N; Topsever P; Kaya A; Karasakal M; Duman C; Dağar A
Tohoku J Exp Med; 2004 Mar; 202(3):173-80. PubMed ID: 15065643
[TBL] [Abstract][Full Text] [Related]
17. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
20. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
